Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy

References

• KassebaumNJAroraMBarberRMGlobal, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the global burden of Disease Study 2015Lancet2016388100531603165827733283
   PubMed Web of Science ®Google Scholar
• Smith-SpanglerCMBhattacharyaJGoldhaber-FiebertJDDiabetes, its treatment, and catastrophic medical spending in 35 developing countriesDiabetes Care201235231932622238276
   PubMed Web of Science ®Google Scholar
• American Diabetes Association2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018Diabetes Care201841Suppl 1S13S2729222373
   PubMed Web of Science ®Google Scholar
• Gómez HuelgasRGómez PeraltaFCarrillo FernándezLHacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMER-GEN y SEMFYC [Towards an integral management of the patient with diabetes and obesity. Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN and SEMFYC]Revista Clínica Española2015215950551426363771
   PubMed Web of Science ®Google Scholar
• BalkauBHomePDVincentMMarreMFreemantleNFactors associated with weight gain in people with type 2 diabetes starting on insulinDiabetes Care20143782108211324824546
   PubMed Web of Science ®Google Scholar
• ChicoAVidal-RíosPSubiràMNovialsAThe continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic controlDiabetes Care20032641153115712663589
   PubMed Web of Science ®Google Scholar
• McCoyRGVan HoutenHKZiegenfussJYShahNDWermersRASmithSAIncreased mortality of patients with diabetes reporting severe hypoglycemiaDiabetes Care20123591897190122699297
   PubMed Web of Science ®Google Scholar
• BarrancoRJGomez-PeraltaFAbreuCIncidence and care-related costs of severe hypoglycaemia requiring emergency treatment in Andalusia (Spain): the PAUEPAD projectDiabet Med201532111520152626118472
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• Gomez-PeraltaFAbreu PadínCCaPPadínCADo we need new treatments for type 2 diabetes?Endocrinol Nutr201461632332824439301
   PubMedGoogle Scholar
• MariABaggerJIFerranniniEHolstJJKnopFKVilsbøllTMechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetesPLoS One201389e7315424019903
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyOzempic: summary of product characteristics2018 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdfAccessed September 3, 2018
   Google Scholar
• LauJBlochPSchäfferLDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue SemaglutideJ Med Chem201558187370738026308095
   PubMed Web of Science ®Google Scholar
• KapitzaCNosekLJensenLHartvigHJensenCBFlintASemaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrelJ Clin Pharmacol201555549750425475122
   PubMed Web of Science ®Google Scholar
• FDA Briefing DocumentEndocrinologic and Metabolic Drugs Advisory Committee MeetingOctober 18, 2017 Semaglutide s.c. OW NDA 209637. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologi-candmetabolicdrugsadvisorycommittee/ucm580460.pdf
   Google Scholar
• ChudleighRBainSCSemaglutideBSCSemaglutide. GLP-1 receptor agonist, treatment of type 2 diabetesDrugs Future2017428479
   Web of Science ®Google Scholar
• NauckMAPetrieJRSestiGA phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, Semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetesDiabetes Care201639223124126358288
   PubMed Web of Science ®Google Scholar
• MarburyTCFlintAJacobsenJBDerving KarsbølJLasseterKPharmacokinetics and tolerability of a single dose of Semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairmentClin Pharmacokinet201756111381139028349386
   PubMed Web of Science ®Google Scholar
• JensenLKupcovaVAroldGPetterssonJHjerpstedJBPharmacokinetics and tolerability of semaglutide in people with hepatic impairmentDiabetes Obes Metab2018204998100529205786
   PubMed Web of Science ®Google Scholar
• JensenLHellebergHRoffelAAbsorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical speciesEur J Pharm Sci2017104314128323117
   PubMed Web of Science ®Google Scholar
• SorliCHarashimaSITsoukasGMEfficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (sustain 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3A trialLancet Diabetes Endocrinol20175425126028110911
   PubMed Web of Science ®Google Scholar
• AhrénBMasmiquelLKumarHEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (sustain 2): a 56-week, double-blind, phase 3A, randomised trialLancet Diabetes Endocrinol20175534135428385659
   PubMed Web of Science ®Google Scholar
• AhmannAJCapehornMCharpentierGEfficacy and safety of once-weekly Semaglutide versus exenatide ER in subjects with type 2 diabetes (sustain 3): a 56-Week, open-label, randomized clinical trialDiabetes Care201841225826629246950
   PubMed Web of Science ®Google Scholar
• ArodaVRBainSCCariouBEfficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (sustain 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3A trialLancet Diabetes Endocrinol20175535536628344112
   PubMed Web of Science ®Google Scholar
• RodbardHWLingvayIReedJSemaglutide added to basal insulin in type 2 diabetes (sustain 5): a randomised, controlled trialJ Clin Endocrinol20181103622912301
   Web of Science ®Google Scholar
• PratleyREArodaVRLingvayISemaglutide versus dulaglutide Once Weekly in patients with type 2 diabetes (sustain 7): a randomised, open-label, phase 3B trialLancet Diabetes Endocrinol20186427528629397376
   PubMed Web of Science ®Google Scholar
• MarsoSPBainSCConsoliASUSTAIN-6 InvestigatorsSemaglutide and cardiovascular outcomes in patients with type 2 diabetesN Engl J Med2016375191834184427633186
   PubMed Web of Science ®Google Scholar
• KivimäkiMKuosmaEFerrieJEOverweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and EuropeLancet Public Health201726e277e28528626830
   PubMed Web of Science ®Google Scholar
• NybergSTBattyGDPenttiJObesity and loss of disease-free years owing to major non-communicable diseases: a multicohort studyLancet Public Health2018310e490e49730177479
   PubMed Web of Science ®Google Scholar
• BlundellJFinlaysonGAxelsenMEffects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesityDiabetes Obes Metab20171991242125128266779
   PubMed Web of Science ®Google Scholar
• de BoerIHBangaloreSBenetosADiabetes and hypertension: a position statement by the American diabetes associationDiabetes Care20174091273128428830958
   PubMed Web of Science ®Google Scholar
• DaviesMJD’AlessioDAFradkinJManagement of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes Association (ADA) and the European association for the study of diabetes (EASD)Diabetes Care201841122669270130291106
   PubMed Web of Science ®Google Scholar
• WarrenMChaykinLTrachtenbargDNayakGWijayasingheNCariouBSemaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the sustain 1–5 trialsDiabetes Obes Metab20182092291229729687620
   PubMed Web of Science ®Google Scholar
• TingDSCheungGCWongTYDiabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a reviewClin Exp Ophthalmol201644426027726716602
   PubMed Web of Science ®Google Scholar
• American Diabetes Association8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018Diabetes Care201841Suppl 1S73S8529222379
   PubMed Web of Science ®Google Scholar
• Gomez-PeraltaFEscalada San MartínFJMenéndez TorreERecomendaciones de la Sociedad Española de diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en La diabetes tipo 2: Actualización 2018 [Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update]Endocrinol Diabetes Nutr2018651061162430366843
   PubMed Web of Science ®Google Scholar
• HinnenDGlucagon-like peptide 1 receptor agonists for type 2 diabetesDiabetes Spectr201730320221028848315
   PubMedGoogle Scholar
• ArodaVRRatnerRThe safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a reviewDiabetes Metab Res Rev201127652854221484979
   PubMed Web of Science ®Google Scholar